Spots Global Cancer Trial Database for To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
Official Title: A Dose-escalation, Single-arm, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 Targeted Chimeric Antigen Receptor T Cell Therapy in Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Who Have Failed Standard Therapy
Study ID: NCT05783570
Conditions
Interventions
Study Description
Brief Summary: To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Detailed Description: A Dose-escalation, Single-arm, Open-Label, Phase 1 Study
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center, Gyeonggi-do, , Korea, Republic of
Severance Hospital, Seoul, , Korea, Republic of
SoonChunHyang University Hospital Seoul, Seoul, , Korea, Republic of
The Catholic University of Korea Seoul ST.MARY'S Hospital., Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
